Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Hepatitis B | Study Protocol

Incidence and predictors of elevated postpartum alanine aminotransferase in chronic hepatitis B mothers: a prospective study protocol

Authors: Shi OuYang, Ziren Chen, Tingting Peng, Yawen Geng, Junchao Qiu, Zhirong Xiao, Calvin Q. Pan

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

The majority of HBeAg-positive mothers with chronic hepatitis B have high levels of viremia and inactive disease with normal alanine aminotransferase (ALT) during pregnancy. In addition, postpartum disease activation and ALT flare have been reported in the range of 15 − 35%. However, the current International Association Guidelines have not provided clear recommendations and a risk-stratified monitoring schedule. Furthermore, data are lacking on the definition of normal ALT in the postpartum period in mothers with chronic hepatitis B. The clinical features and ALT flare patterns in HBeAg-positive mothers versus HBeAg-negative mothers are not fully explored. Thus, we design a cohort study to investigate the aforementioned area and generate data to assist healthcare providers in better managing mothers with hepatitis B. We aim to assess the frequency of postpartum ALT flares and predictors for such events.

Method

This study is a single-center and prospective cohort study (n = 360) that consists of two groups of patients including HBsAg-positive mothers (n = 120) and healthy mothers without HBV infection (n = 240). In HBeAg-positive mothers, antiviral therapy during late pregnancy is permitted to prevent Mother-to-child transmission (MTCT) but discontinued at delivery if there is no further indication for the treatment. Mothers are enrolled at the gestational weeks of 12–24. After delivery, both mothers and their infants will be followed up until postpartum week 24. Clinical and laboratory data are collected every 4 weeks during the study except there are no follow-up visits at the postpartum weeks 16 and 20. The primary objective is the proportion of patients with postpartum ALT flares. The secondary objectives are independent risk factors during pregnancy for predicting postpartum ALT flares and the normal range of postpartum ALT levels in healthy mothers.

Discussion

The current study focuses on the incidence of postpartum ALT flares in mothers with chronic hepatitis B including subgroup analysis based on HBeAg status. The data will have several clinical implications, such as providing evidence for an appropriate monitoring schedule in CHB mothers after delivery. Further analyses on predictors of such events may assist clinicians in identifying mothers who might develop severe postpartum ALT flares. The data generated from healthy mothers have the potential to identify the patterns of ALT changes during pregnancy and postpartum, so we can gain a better understanding of the normal range of ALT in this subpopulation.

Trial Registration Number at the Chinese Clinical Trial Registry

ChiCTR2200061130.
Literature
1.
go back to reference WHO. Global hepatitis report. Geneva: World Health Organization. 2017 WHO. Global hepatitis report. Geneva: World Health Organization. 2017
2.
go back to reference Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, Salvadori N, Decker L, Traisathit P, Sirirungsi W, et al. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis. 2016;16:393.CrossRefPubMedPubMedCentral Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, Salvadori N, Decker L, Traisathit P, Sirirungsi W, et al. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis. 2016;16:393.CrossRefPubMedPubMedCentral
3.
go back to reference Wei Zheng F, Cui X, Gong. Analysis of the prevalence of HBsAg and e antigen in women of childbearing age in China. Chin J Vaccines Immun. 2010;16:496–9. Wei Zheng F, Cui X, Gong. Analysis of the prevalence of HBsAg and e antigen in women of childbearing age in China. Chin J Vaccines Immun. 2010;16:496–9.
4.
go back to reference European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L: EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.CrossRef European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L: EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.CrossRef
5.
go back to reference Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.CrossRefPubMed Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.CrossRefPubMed
6.
go back to reference Guiqiang Wang Z, Duan F, Wang, et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition). J Practical Liver Disease. 2020;23(01):9–32. Guiqiang Wang Z, Duan F, Wang, et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition). J Practical Liver Disease. 2020;23(01):9–32.
7.
go back to reference Yi W, Pan CQ, Li MH, Wan G, Lv YW, Liu M, Hu YH, Zhang ZY, Xie Y. The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B. Am J Gastroenterol. 2018;113(5):686–93.CrossRefPubMed Yi W, Pan CQ, Li MH, Wan G, Lv YW, Liu M, Hu YH, Zhang ZY, Xie Y. The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B. Am J Gastroenterol. 2018;113(5):686–93.CrossRefPubMed
8.
go back to reference Giles M, Visvanathan K, Lewin S, Bowden S, Locarnini S, Spelman T, Sasadeusz J. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut. 2015;64(11):1810–5.CrossRefPubMed Giles M, Visvanathan K, Lewin S, Bowden S, Locarnini S, Spelman T, Sasadeusz J. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut. 2015;64(11):1810–5.CrossRefPubMed
9.
go back to reference Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, Zhang H, Zou H, Zhu B, Zhao W, et al. Tenofovir to prevent Hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–34.CrossRefPubMed Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, Zhang H, Zou H, Zhu B, Zhao W, et al. Tenofovir to prevent Hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–34.CrossRefPubMed
10.
go back to reference Pan CQ, Dai E, Bhamidimarri KR, Zeng Z, Yin P. Clinical features of Chronic Hepatitis B in Treatment-naive asian patients with positive HBeAg and coexisting precore and/or basal core promoter mutations. J Clin Gastroenterol. 2017;51(3):261–7.CrossRefPubMed Pan CQ, Dai E, Bhamidimarri KR, Zeng Z, Yin P. Clinical features of Chronic Hepatitis B in Treatment-naive asian patients with positive HBeAg and coexisting precore and/or basal core promoter mutations. J Clin Gastroenterol. 2017;51(3):261–7.CrossRefPubMed
11.
go back to reference Li MR, Xu ZG, Lu JH, Zheng HW, Ye LH, Liu YY, Liu ZQ, Zhang HC, Huang Y, Dai EH, et al. Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutations. J Viral Hepat. 2020;27(10):1044–51.CrossRefPubMed Li MR, Xu ZG, Lu JH, Zheng HW, Ye LH, Liu YY, Liu ZQ, Zhang HC, Huang Y, Dai EH, et al. Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutations. J Viral Hepat. 2020;27(10):1044–51.CrossRefPubMed
12.
go back to reference Luo Y, Pan M, Ning M, Chenyu X, Liu L, Chen L, Chen T, Biyun X, Yali H, Zhou YH. High mutation prevalence of precore and basal core promoter in pregnant women who underwent spontaneous HBeAg seroconversion within one year postpartum. Dig Liver Dis. 2020;52(2):199–204.CrossRefPubMed Luo Y, Pan M, Ning M, Chenyu X, Liu L, Chen L, Chen T, Biyun X, Yali H, Zhou YH. High mutation prevalence of precore and basal core promoter in pregnant women who underwent spontaneous HBeAg seroconversion within one year postpartum. Dig Liver Dis. 2020;52(2):199–204.CrossRefPubMed
13.
go back to reference Kushner T, Park C, Masand D, Rosenbluth E, Carroll C, Grace M, Rodriguez-Rivas C, De La Cruz H, Overbey J, Sperling R. Prevalence of elevated alanine aminotransferase (ALT) in pregnancy: a cross-sectional labor and delivery-based assessment. Medicine. 2022;101(40):e30408.CrossRefPubMedPubMedCentral Kushner T, Park C, Masand D, Rosenbluth E, Carroll C, Grace M, Rodriguez-Rivas C, De La Cruz H, Overbey J, Sperling R. Prevalence of elevated alanine aminotransferase (ALT) in pregnancy: a cross-sectional labor and delivery-based assessment. Medicine. 2022;101(40):e30408.CrossRefPubMedPubMedCentral
14.
go back to reference Lee SM, Park JS, Han YJ, Kim W, Bang SH, Kim BJ, Park CW, Kim MY. Elevated alanine aminotransferase in early pregnancy and subsequent development of gestational diabetes and Preeclampsia. J Korean Med Sci. 2020;35(26):e198.CrossRefPubMedPubMedCentral Lee SM, Park JS, Han YJ, Kim W, Bang SH, Kim BJ, Park CW, Kim MY. Elevated alanine aminotransferase in early pregnancy and subsequent development of gestational diabetes and Preeclampsia. J Korean Med Sci. 2020;35(26):e198.CrossRefPubMedPubMedCentral
15.
go back to reference Liu J, Wang J, Qi C, Cao F, Tian Z, Guo D, Yan T, Li Q, Yang S, Fu J, et al. Baseline Hepatitis B Virus Titer predicts initial postpartum hepatic flare: a Multicenter prospective study. J Clin Gastroenterol. 2018;52(10):902–7.CrossRefPubMed Liu J, Wang J, Qi C, Cao F, Tian Z, Guo D, Yan T, Li Q, Yang S, Fu J, et al. Baseline Hepatitis B Virus Titer predicts initial postpartum hepatic flare: a Multicenter prospective study. J Clin Gastroenterol. 2018;52(10):902–7.CrossRefPubMed
Metadata
Title
Incidence and predictors of elevated postpartum alanine aminotransferase in chronic hepatitis B mothers: a prospective study protocol
Authors
Shi OuYang
Ziren Chen
Tingting Peng
Yawen Geng
Junchao Qiu
Zhirong Xiao
Calvin Q. Pan
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Hepatitis B
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02966-2

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.